Can Preferentially Prescribing Angiotensin II Receptor Blockers (ARBs) over Angiotensin-Converting Enzyme Inhibitors (ACEIs) Decrease Dementia Risk and Improve Brain Health Equity? uri icon

authors

  • Zachary Marcum, PharmD, PhD
  • Cohen, Jordana B
  • Larson, Eric B
  • Williamson, Jeff
  • Bress, Adam P

publication date

  • January 1, 2022